Osteoporosis Risk Calculator (FRAX)

Assess your 10-year fracture risk probability using the FRAX algorithm. Evaluate bone health and osteoporosis risk factors.

Female
Male
years
Enter age between 40 and 90 years
40 65 years 90
kg
Body weight in kilograms
30 kg 70 kg 200 kg
cm
Current height in centimeters
120 cm 165 cm 220 cm
kg/m²
Calculated from weight and height
Normal weight
Previous Fracture
Have you had a fracture as an adult (after age 40)?
Parent Hip Fracture
Did either parent have a hip fracture?
Current Smoking
Do you currently smoke tobacco?
Glucocorticoid Use
Have you taken oral glucocorticoids for 3+ months?
Rheumatoid Arthritis
Do you have rheumatoid arthritis?
Secondary Osteoporosis
Do you have conditions associated with osteoporosis (e.g., type 1 diabetes, hyperthyroidism)?
Alcohol Consumption (≥3 units/day)
Do you consume 3 or more units of alcohol daily?

Bone Mineral Density (BMD) - Optional

If you have a DXA scan result, enter your T-score for more accurate assessment

SD
T-score at femoral neck (if available)
Calculating fracture risk...

Understanding Osteoporosis and Fracture Risk

Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. The FRAX® tool, developed by the World Health Organization (WHO), calculates the 10-year probability of a major osteoporotic fracture (hip, spine, forearm, or shoulder) or hip fracture.

Clinical Importance: Osteoporosis is often called a "silent disease" because bone loss occurs without symptoms. The first sign of osteoporosis is often a fracture after a minor fall or even from simple activities like bending over or coughing. Fractures, especially hip fractures, can lead to significant morbidity, mortality, and reduced quality of life.

200M
People affected worldwide
1 in 3
Women over 50 will experience fractures
1 in 5
Men over 50 will experience fractures
24%
Hip fracture patients die within one year

FRAX Risk Factors Explained

FRAX Algorithm Risk Factors:
1. Age: Risk increases significantly with age
2. Sex: Women are at higher risk than men
3. Weight & Height: Low BMI is a significant risk factor
4. Previous Fracture: Especially after age 40
5. Parent Hip Fracture: Strong genetic component
6. Current Smoking: Reduces bone density
7. Glucocorticoids: Long-term use increases risk
8. Rheumatoid Arthritis: Chronic inflammation affects bones
9. Secondary Osteoporosis: Various medical conditions
10. Alcohol Consumption: ≥3 units/day increases risk

Bone Density T-score Interpretation

Normal
(T-score ≥ -1.0)
Osteopenia
(-1.0 to -2.5)
Osteoporosis
(T-score ≤ -2.5)
Bone Mineral Density (BMD) relative to young adult mean
Risk Factor Relative Risk Increase Clinical Significance Modifiable
Age (per decade after 50) 2-3x Most powerful predictor of fracture risk No
Previous Fracture 2x Doubles risk of subsequent fractures Partially
Parent Hip Fracture 1.5-2x Strong genetic predisposition No
Current Smoking 1.5-2x Accelerates bone loss Yes
Glucocorticoid Use 2-3x Inhibits bone formation Sometimes
Low BMI (<20 kg/m²) 1.5-2x Less weight-bearing stress on bones Sometimes

Bone Mineral Density (BMD) and T-scores

T-score Classification (WHO Criteria):
• Normal: T-score ≥ -1.0
• Osteopenia (Low Bone Mass): T-score between -1.0 and -2.5
• Osteoporosis: T-score ≤ -2.5
• Severe Osteoporosis: T-score ≤ -2.5 with one or more fragility fractures
T-score Range Diagnosis 10-Year Fracture Risk Recommended Action
> -1.0 Normal Low (<10%) Lifestyle measures, reassess in 5-10 years
-1.0 to -1.49 Mild Osteopenia Low-Moderate (10-15%) Lifestyle measures, calcium/vitamin D, reassess in 3-5 years
-1.5 to -1.99 Moderate Osteopenia Moderate (15-20%) Consider treatment if other risk factors present
-2.0 to -2.49 Severe Osteopenia High (20-30%) Strongly consider pharmacological treatment
≤ -2.5 Osteoporosis Very High (>30%) Pharmacological treatment recommended

Expert Insights

Dr. Sarah Johnson, Endocrinologist: "Early detection of osteoporosis is crucial. A 10% bone loss in the vertebrae doubles fracture risk. Regular screening after age 65 for women and 70 for men can prevent devastating fractures."

Prof. Michael Chen, Orthopedic Surgeon: "Hip fractures are not just broken bones - they're life-changing events. 40% of patients cannot walk independently again, and 60% require assistance with daily activities one year later."

Treatment Timeline for Osteoporosis

Immediate (0-6 months)

Start calcium (1200 mg/day) and vitamin D (800-1000 IU/day). Begin weight-bearing exercises. Assess fall risk at home.

Short-term (6-12 months)

Consider pharmacological therapy if high risk. Monitor adherence. Repeat DXA scan after 1-2 years of treatment.

Long-term (1-5 years)

Continuous monitoring. Consider drug holidays for bisphosphonates after 3-5 years. Regular reassessment of fracture risk.

Maintenance (5+ years)

Lifelong lifestyle modifications. Periodic reassessment. Transition to different therapies if needed.

Prevention and Management Strategies

Nutrition
Adequate calcium (1200 mg/day) and vitamin D (800-1000 IU/day) intake. Protein for muscle strength.
Exercise
Weight-bearing and resistance exercises. Balance training to prevent falls.
Lifestyle Modifications
Smoking cessation, limiting alcohol to ≤2 units/day, fall prevention strategies.
Pharmacological Treatment
Bisphosphonates, RANKL inhibitors, parathyroid hormone analogs, SERMs based on individual risk.
Fall Prevention
Home safety assessment, vision checks, medication review, balance training.
Monitoring
Regular BMD testing every 1-2 years during treatment, assessment of treatment adherence.

Osteoporosis in Special Populations

1

Postmenopausal Women: Rapid bone loss occurs in the first 5-10 years after menopause due to estrogen deficiency. All women over 65 should be screened for osteoporosis. Hormone replacement therapy can be considered for women with early menopause.

2

Men: Osteoporosis in men is underdiagnosed and undertreated. One in five men over 50 will experience an osteoporotic fracture. Secondary causes are common and should be evaluated, including hypogonadism, alcohol abuse, and glucocorticoid use.

3

Glucocorticoid-Induced Osteoporosis: Bone loss can occur rapidly with glucocorticoid use. Prevention and treatment should be considered for anyone taking ≥5 mg prednisone daily for ≥3 months. Bisphosphonates are first-line therapy.

4

Young Adults with Risk Factors: Peak bone mass is achieved by age 30. Lifestyle factors in youth significantly impact future fracture risk. Eating disorders, excessive exercise, and certain medications can affect bone health in young adults.

Clinical Note: This calculator provides an estimate of fracture risk based on the FRAX algorithm. It is not a substitute for clinical evaluation by a healthcare professional. Diagnosis and treatment decisions should be made in consultation with a physician, considering individual patient circumstances and additional risk factors not included in this calculation.

Frequently Asked Questions

The FRAX® tool (Fracture Risk Assessment Tool) was developed by the World Health Organization (WHO) to evaluate fracture risk of patients. It is based on data from population-based cohorts from Europe, North America, Asia, and Australia. The tool calculates the 10-year probability of hip fracture and major osteoporotic fracture (clinical spine, forearm, hip, or shoulder fracture). FRAX has been validated in multiple independent cohorts worldwide and is widely used in clinical guidelines to guide treatment decisions. It accounts for country-specific differences in fracture rates and mortality.

Bone density peaks around age 30, after which gradual bone loss begins. For women, the most rapid bone loss occurs in the first 5-10 years after menopause. The U.S. Preventive Services Task Force recommends screening for osteoporosis with bone measurement testing in women aged 65 years and older, and in younger women whose fracture risk is equal to or greater than that of a 65-year-old white woman with no additional risk factors. Men should be evaluated at age 70 or earlier if they have risk factors. Early screening (age 50) may be recommended for those with strong risk factors like previous fractures, rheumatoid arthritis, or long-term steroid use.

While osteoporosis cannot be completely "cured" or "reversed" to normal young adult bone density, it can be effectively treated. Current medications can reduce fracture risk by 30-70% by slowing bone loss, increasing bone density, and improving bone quality. With appropriate treatment and lifestyle modifications, fracture risk can be significantly reduced. Some newer medications like teriparatide and romosozumab can actually stimulate new bone formation. The goal of treatment is to prevent fractures, reduce pain, and maintain mobility and quality of life.

Osteopenia refers to low bone density that is not severe enough to be classified as osteoporosis. It is defined by a T-score between -1.0 and -2.5. Osteoporosis is more severe, with a T-score of -2.5 or lower. While osteopenia indicates increased fracture risk compared to normal bone density, the risk is lower than with osteoporosis. Not everyone with osteopenia will develop osteoporosis, but it represents an opportunity for preventive measures to reduce further bone loss. Treatment decisions for osteopenia depend on additional risk factors and calculated fracture risk.

The frequency of bone density testing depends on individual circumstances. For individuals with normal bone density or mild osteopenia, testing every 10-15 years may be sufficient. For those with moderate osteopenia, testing every 3-5 years is recommended. For patients on osteoporosis treatment, monitoring every 1-2 years is typical to assess treatment response. However, decisions about testing frequency should be individualized based on age, risk factors, and treatment status. Medicare covers bone density testing every 24 months for qualified individuals.
Latest Research Updates

2023 Study in JAMA: New monoclonal antibody treatments show 75% reduction in vertebral fractures compared to placebo. These novel therapies target specific bone remodeling pathways with fewer side effects.

2022 NEJM Publication: Combination therapy with teriparatide followed by bisphosphonates shows superior fracture prevention compared to monotherapy in severe osteoporosis cases.

2023 Lancet Digital Health: AI algorithms can now predict fracture risk from routine X-rays with 89% accuracy, potentially revolutionizing early detection.